INTS

Intensity Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website intensitytherapeutics.com
Employees(FY) -
ISIN US45828J1034

Performance

-12.24%

+23.08%

-26.56%

-53.53%

+27.27%

YTD

-54.47%

Profile

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. Its lead product candidate includes INT230-6, a clinical trial for the treatment of refractory solid tumors and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. The company was incorporated in 2012 and is headquartered in Westport, Connecticut.

Advanced Technical Analysis

Technical Analysis of INTS 2025-01-31

The stock indicators reflect a bearish sentiment, with a Moving Average Score of 16 and a Technical Score of 16 indicating weak momentum, while the Oscillators Score of 50 suggests a neutral stance. Overall, the low scores in both moving averages and technical analysis point to a lack of bullish momentum in the stock.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of INTS

Stock Rank

Recent News & Updates

2025-01-27 19:00
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ('INVINCIBLE-3 Study') Following Periodic Review(Prnewswire)
2025-01-09 19:00
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6(Prnewswire)
2024-12-12 19:10
Intensity Therapeutics reports positive results of INT230-6 in breast cancer(Yahoo Finance)
2024-12-11 19:00
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer(Prnewswire)
2024-11-20 19:00
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement(Prnewswire)
2024-11-17 19:00
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ('INVINCIBLE-3 Study') in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)(Prnewswire)
2024-11-13 03:06
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update(Prnewswire)
2024-11-07 19:01
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting(Prnewswire)
2024-10-30 21:00
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)(Prnewswire)
2024-09-03 20:00
Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Prnewswire)
2024-08-08 04:19
Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update(Prnewswire)
2024-07-08 20:01
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma(Prnewswire)
2024-05-14 20:01
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors(Prnewswire)
2024-05-09 22:48
Intensity Therapeutics Collaborates With Swiss Group on Clinical Research for Breast Cancer Trial(Yahoo Finance)
2024-05-09 20:01
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate(Prnewswire)
2024-05-09 11:54
INTS Stock Earnings: Intensity Therapeutics Reported Results for Q1 2024(Investorplace)
2024-05-09 04:08
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update(Prnewswire)
2024-04-01 20:01
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024(Prnewswire)
2024-03-26 11:53
INTS Stock Earnings: Intensity Therapeutics Beats EPS for Q4 2023(Investorplace)
2024-03-25 20:01
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares(Globenewswire)
2024-03-14 04:09
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update(Prnewswire)
2024-03-13 20:00
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024(Prnewswire)
2024-02-20 19:01
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference(Prnewswire)
2024-01-02 19:01
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program(Prnewswire)
2023-12-11 19:01
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer(Prnewswire)
2023-12-07 22:12
Why Is Intensity Therapeutics (INTS) Stock Up 133% Today?(Investorplace)
2023-12-07 19:30
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS(Prnewswire)
2023-11-30 19:01
Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium(Prnewswire)
2023-11-12 19:01
Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update(Prnewswire)
2023-11-01 19:01
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023(Prnewswire)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.